首页> 美国卫生研究院文献>other >Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer
【2h】

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer

机译:DUSP4缺失导致MAPK通路的激活促进基底样乳腺癌的癌症干细胞样表型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Basal-like breast cancer (BLBC) is an aggressive disease that lacks a clinically-approved targeting therapy. Traditional chemotherapy is effective in BLBC, but it spares the cancer stem cell (CSC)-like population which is likely to contribute to cancer recurrence after the initial treatment. DUSP4 is a negative regulator of the MAPK pathway that is deficient in highly aggressive BLBCs treated with chemotherapy, leading to aberrant MAPK activation and resistance to taxane-induced apoptosis. Herein, we investigated how DUSP4 regulates the MEK and JNK pathways in modifying CSC-like behavior. DUSP4 loss increased mammosphere formation and the expression of the CSC-promoting cytokines IL-6 and IL-8. These effects were caused in part by loss of control of the MEK and JNK pathways and involved downstream activation of the ETS-1 and c-JUN transcription factors. Enforced expression of DUSP4 in reduced the CD44+/CD24- population in multiple BLBC cell lines in a MEK-dependent manner, limiting tumor formation of claudin-low SUM159PT cells in mice. Our findings support the evaluation of MEK and JNK pathway inhibitors as therapeutic agents in BLBC in order to eliminate the CSC population.
机译:基底样乳腺癌(BLBC)是一种侵袭性疾病,缺乏临床认可的靶向治疗。传统的化学疗法在BLBC中是有效的,但它避免了癌症干细胞(CSC)样的人群,这很可能在初始治疗后有助于癌症复发。 DUSP4是MAPK途径的负调节剂,在用化学疗法治疗的高度侵袭性BLBC中缺乏,导致异常MAPK活化和对紫杉烷诱导的细胞凋亡的抵抗。在本文中,我们研究了DUSP4如何在修饰CSC样行为中调节MEK和JNK途径。 DUSP4丢失增加了乳球形成以及促进CSC的细胞因子IL-6和IL-8的表达。这些影响部分是由于对MEK和JNK通路失去控制,并涉及ETS-1和c-JUN转录因子的下游激活。 DUSP4的增强表达以MEK依赖性方式减少了多个BLBC细胞系中CD44 + / CD24-的数量,从而限制了小鼠中低claudin-SUM159PT细胞的肿瘤形成。我们的发现支持评估MEK和JNK途径抑制剂作为BLBC中的治疗药物以消除CSC人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号